MK-8189
Total Payments
$17.2M
Transactions
1,343
Doctors
41
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $486,666 | 112 | 9 |
| 2019 | $182,868 | 18 | 2 |
| 2018 | $4.3M | 214 | 0 |
| 2017 | $12.3M | 999 | 35 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.1M | 1,021 | 99.4% |
| Consulting Fee | $69,400 | 26 | 0.4% |
| Travel and Lodging | $27,880 | 102 | 0.2% |
| Food and Beverage | $10,916 | 194 | 0.1% |
Payments by Type
Research
$17.1M
1,021 transactions
General
$108,196
322 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 using Risperidone as Active Control in Subjects Experiencing an AcuteEpisode of Schizophrenia. | Merck Sharp & Dohme Corporation | $16.0M | 1 |
| A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics andPharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients | Merck Sharp & Dohme Corporation | $382,314 | 0 |
| A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia | Merck Sharp & Dohme Corporation | $298,192 | 0 |
| A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Diltiazem on the Single-Dose Pharmacokinetics of MK-8189 in Healthy Subjects. | Merck Sharp & Dohme Corporation | $200,218 | 0 |
| A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titration Regimens in Young Adult Participants With Schizophrenia and to Evaluate the Safety, Tolerability and Pharmacokinetics of MK 8189 in Elderly Participants With Schizophrenia | Merck Sharp & Dohme Corporation | $171,711 | 0 |
| A multiple-dose clinical study to evaluate the safety, tolerability,pharmacokinetics and QTc effect of MK-8189 in participants with schizophrenia and healthy participants | Merck Sharp & Dohme Corporation | $112,912 | 0 |
| A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies | Merck Sharp & Dohme Corporation | $259.05 | 0 |
Top Doctors Receiving Payments for MK-8189 — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Psychiatry | Sherman Oaks, CA | $1,457 | 14 |
| , M.D | Psychiatry | Orange, CA | $1,408 | 9 |
| , MD | Psychiatry | Atlanta, GA | $1,344 | 5 |
| , MD, PHD | Anatomic Pathology & Clinical Pathology | Overland Park, KS | $1,336 | 14 |
| , M.D | Psychiatry | Hoffman Estates, IL | $1,319 | 13 |
| , D.O | Psychiatry | Maitland, FL | $1,316 | 13 |
| , MD | Psychiatry | Desoto, TX | $1,271 | 12 |
| , M.D | Psychiatry | Catonsville, MD | $1,238 | 1 |
| , MD | Psychiatry | Oakland Park, FL | $1,225 | 11 |
| , M.D | Psychiatry | Lauderhill, FL | $1,211 | 11 |
| , MD | Psychiatry | San Diego, CA | $1,169 | 8 |
| , D.O | Psychiatry | Saint Louis, MO | $1,025 | 8 |
| , M.D | Psychiatry | Orangeburg, NY | $1,015 | 10 |
| , M.D | Neurology | Arcadia, CA | $1,004 | 8 |
| , M.D | Psychiatry | Dallas, TX | $953.94 | 10 |
| , M.D | Child & Adolescent Psychiatry | Houston, TX | $683.15 | 5 |
| James Booker | — | Shreveport, LA | $200.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $17.2M
- Total Doctors 41
- Transactions 1,343
About MK-8189
MK-8189 is a drug associated with $17.2M in payments to 41 healthcare providers, recorded across 1,343 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $486,666 was paid across 112 transactions to 9 doctors.
The most common payment nature for MK-8189 is "Unspecified" ($17.1M, 99.4% of total).
MK-8189 is associated with 7 research studies, including "A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 using Risperidone as Active Control in Subjects Experiencing an AcuteEpisode of Schizophrenia." ($16.0M).